Abolfazl Razzaghdoust1, Bahram Mofid2, Parvin Peyghambarlou3. 1. Student Research Committee, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Radiation Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Shahrdari St, Tajrish Sq, Tehran, 1989934148, Iran. mofid429@sbmu.ac.ir. 3. Department of Radiation Oncology, Shohada-e-Tajrish Medical Center, Shahid Beheshti University of Medical Sciences, Shahrdari St, Tajrish Sq, Tehran, 1989934148, Iran.
Abstract
PURPOSE: Chemotherapy-induced anemia is a frequent complication of systemic chemotherapy and is associated with decreased functional capacity and quality of life. The objective of this study was to identify the candidate variables most likely to be associated with chemotherapy-induced severe anemia (hemoglobin < 8 g/dL) in patients treated with cytotoxic chemotherapy. METHODS: A total of 14 clinical and laboratory covariates were prospectively evaluated at baseline in a cohort of consecutive cancer patients receiving cytotoxic chemotherapy. The anemia risk category for each chemotherapy regimen used was determined based on pivotal trials published in the literature. All regimens were classified to three categories (high risk, intermediate risk, and low risk). Logistic regression analysis adjusted for the regimen risk was used to determine the candidate risk factors associated with chemotherapy-induced anemia. RESULTS: A total of 305 patients were included in the study. Administration of high-risk regimens (i.e., regimens with ≥ 20% risk of anemia in a pivotal trial) was demonstrated to be a novel independent predictive factor for severe anemia (odds ratio 3.33, p = 0.005). Considering regimen risk as an adjustment factor, 5 readily available predictors including low hemoglobin, body mass index (BMI) less than 23 kg/m2, low hematocrit, high haptoglobin, and high ferritin were associated with the outcome. CONCLUSIONS: The application of these candidate predictors would be helpful in classifying patients at risk for severe anemia, who might be appropriate candidates for prophylactic erythropoietin. Multivariable models including such promising candidate predictors need to be developed.
PURPOSE: Chemotherapy-induced anemia is a frequent complication of systemic chemotherapy and is associated with decreased functional capacity and quality of life. The objective of this study was to identify the candidate variables most likely to be associated with chemotherapy-induced severe anemia (hemoglobin < 8 g/dL) in patients treated with cytotoxic chemotherapy. METHODS: A total of 14 clinical and laboratory covariates were prospectively evaluated at baseline in a cohort of consecutive cancer patients receiving cytotoxic chemotherapy. The anemia risk category for each chemotherapy regimen used was determined based on pivotal trials published in the literature. All regimens were classified to three categories (high risk, intermediate risk, and low risk). Logistic regression analysis adjusted for the regimen risk was used to determine the candidate risk factors associated with chemotherapy-induced anemia. RESULTS: A total of 305 patients were included in the study. Administration of high-risk regimens (i.e., regimens with ≥ 20% risk of anemia in a pivotal trial) was demonstrated to be a novel independent predictive factor for severe anemia (odds ratio 3.33, p = 0.005). Considering regimen risk as an adjustment factor, 5 readily available predictors including low hemoglobin, body mass index (BMI) less than 23 kg/m2, low hematocrit, high haptoglobin, and high ferritin were associated with the outcome. CONCLUSIONS: The application of these candidate predictors would be helpful in classifying patients at risk for severe anemia, who might be appropriate candidates for prophylactic erythropoietin. Multivariable models including such promising candidate predictors need to be developed.
Entities:
Keywords:
Cancer; Chemotherapy; Predictor; Severe anemia
Authors: Gary H Lyman; Ernst R Berndt; Joel D Kallich; M Haim Erder; William H Crown; Stacey R Long; Howard Lee; Xue Song; Stan N Finkelstein Journal: Value Health Date: 2005 Mar-Apr Impact factor: 5.725
Authors: N Chaumard; S Limat; C Villanueva; V Nerich; P Fagnoni; F Bazan; L Chaigneau; E Dobi; L Cals; X Pivot Journal: Breast Date: 2011-11-26 Impact factor: 4.380
Authors: Mark Vincent; George Dranitsaris; Sunil Verma; Cathy Lau; Pere Gascon; Simon Van Belle; Heinz Ludwig Journal: Support Care Cancer Date: 2006-11-21 Impact factor: 3.603
Authors: Peter J Barrett-Lee; Heinz Ludwig; Gunnar Birgegård; Carsten Bokemeyer; Pere Gascón; Paris A Kosmidis; Maciej Krzakowski; Johan W R Nortier; Gail Kongable; Maurice Schneider; Dirk Schrijvers; Simon J Van Belle Journal: Oncology Date: 2006-02-21 Impact factor: 2.935
Authors: M Lind; C Vernon; D Cruickshank; P Wilkinson; T Littlewood; N Stuart; C Jenkinson; P Grey-Amante; H Doll; D Wild Journal: Br J Cancer Date: 2002-04-22 Impact factor: 7.640
Authors: Parth Sharma; Josh Thomas Georgy; Anand George Andrews; Ajoy Oommen John; Anjana Joel; Raju Titus Chacko; Prasanna Samuel Premkumar; Ashish Singh Journal: Support Care Cancer Date: 2022-03-21 Impact factor: 3.359